823
Participants
Start Date
May 29, 2015
Primary Completion Date
January 14, 2022
Study Completion Date
January 14, 2022
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Ichinomiya
Komaki
Kōnan
Nagakute
Nagoya
Okazaki
Toyoake
Toyohashi
Toyokawa
Toyota
Yatomi
Daisen
Hirosaki
Misawa
Kashiwa
Yachiyo
Matsuyama
Tōon
Tsuruga
Yoshida
Kitakyushu
Koga
Koga
Kurume
Omuta
Aizu-Wakamatsu
Iwaki
Kōriyama
Shirakawa
Hashima
Kakamigahara
Minokamo
Okazai
Ōgaki
Maebashi
Ōta
Fukuyama
Hakodate
Kitami
Kushiro
Obihiro
Otaru
Sapporo
Akashi
Amagasaki
Himeji
Kobe
Nishinomiya
Hitachi
Kasama
Ryūgasaki
Tsuchiura
Tsukuba
Hakusan
Kaga
Kahoku
Kanazawa
Nanao
Morioka
Kida
Marugame
Takamatsu
Fujisawa
Hiratsuka
Isehara
Kamakura
Kanazawachō
Sagamihara
Yokohama
Yokosuka
Nankoku
Matsuzaka
Tsu
Yokkaichi
Ishinomaki
Murata
Natori-shi
Ōsaki
Sendai
Matsumoto
Saku
Ōmura
Sasebo
Ikoma
Tenri
Yamatotakada
Yufu
Kurashiki
Naha
Tomigusuku
Urasoe
Hirakata
Kawachi-Nagano
Moriguchi
Neyagawa
Sayama
Suita
Kawagoe
Kitaadachi
Koshigaya
Moriyama
Ōtsu
Izumi
Izumo
Hamamatsu
Izunokuni
Sunto
Shimotsuga
Shimotsuke
Utsunomiya
Komatsushimachō
Bunkyo-ku
Chiyoda-ku
Chuo-ku
Itabashi-ku
Koto-ku
Machida
Meguro-ku
Minato-ku
Musashino
Ōta-ku
Shinagawa-ku
Shinjuku-ku
Yonago
Kurobe-shi
Takaoka
Sakata
Tsuruoka
Iwakuni
Ube
Kofu
Akita
Aomori
Chiba
Fukui
Fukuoka
Gifu
Ibaraki
Kagoshima
Kochi
Kumamoto
Kyoto
Miyazaki
Nagano
Nagasaki
Niigata
Okayama
Okinawa
Osaka
Saga
Saitama
Shizuoka
Tokushima
Toyama
Yamagata
Lead Sponsor
Takeda
INDUSTRY